These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
61 related articles for article (PubMed ID: 184804)
21. Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium. Brunkhorst D; von der Leyen H; Meyer W; Schmidt-Schumacher C; Scholz H Arzneimittelforschung; 1988 Sep; 38(9):1293-8. PubMed ID: 2852013 [TBL] [Abstract][Full Text] [Related]
22. [Phosphodiesterase inhibition as a therapeutic principle]. Scholz H Z Kardiol; 1994; 83 Suppl 2():1-5. PubMed ID: 8091820 [TBL] [Abstract][Full Text] [Related]
23. Selective phosphodiesterase inhibition and alterations of cardiac function by alkylated xanthines. Mushlin P; Boerth RC; Wells JN Mol Pharmacol; 1981 Jul; 20(1):179-89. PubMed ID: 6270531 [No Abstract] [Full Text] [Related]
24. Haemodynamic effects of Ro 13-6438, a new inotropic agent with vasodilating properties. Braun S; Shargorodsky B; Talit U; Laniado S Drugs Exp Clin Res; 1986; 12(5):381-4. PubMed ID: 3720522 [TBL] [Abstract][Full Text] [Related]
25. Cardiovascular effects of a new inotropic agent, U. K. 14275, in patients with coronary heart disease. Hutton I; Hillis WS; Langhan CE; Conely JM; Lawrie TD Br J Clin Pharmacol; 1977 Oct; 4(5):513-7. PubMed ID: 911601 [TBL] [Abstract][Full Text] [Related]
26. Effect of 2-(4-benzyl-piperidino)-1-(4-hydroxyphenyl)-1-propranolol on adenylate cyclase and 3,5'-cyclic AMP phosphodiesterase in vitro. Yamashita Y; Kawai M; Hotta K Jpn J Pharmacol; 1976 Jun; 26(3):391-4. PubMed ID: 185445 [No Abstract] [Full Text] [Related]
27. Inotropic therapy of heart failure. Editorial comments on: Vasodilation and mechanoenergetic inefficiency dominates the effect of the "Ca2+ sensitizer" MCI-154 in intact pigs. Duncker DJ; Verdouw PD Scand Cardiovasc J; 2002 May; 36(3):131-5. PubMed ID: 12079634 [No Abstract] [Full Text] [Related]
29. New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors. Devillers I; Pevet I; Jacobelli H; Durand C; Fasquelle V; Puaud J; Gaudillière B; Idrissi M; Moreau F; Wrigglesworth R Bioorg Med Chem Lett; 2004 Jun; 14(12):3303-6. PubMed ID: 15149695 [No Abstract] [Full Text] [Related]
30. 2-(Alkylthio)-1,2,4-triazolo[1,5-a]pyrimidines as adenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitors with potential as new cardiovascular agents. Novinson T; Springer RH; O'Brien DE; Scholten MB; Miller JP; Robins RK J Med Chem; 1982 Apr; 25(4):420-6. PubMed ID: 6279846 [TBL] [Abstract][Full Text] [Related]
31. Positive inotropic effect of levosimendan is correlated to its stereoselective Ca2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition. Kaheinen P; Pollesello P; Hertelendi Z; Borbély A; Szilágyi S; Nissinen E; Haikala H; Papp Z Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):74-8. PubMed ID: 16433895 [TBL] [Abstract][Full Text] [Related]
32. Synthesis and cardiotonic activity of a series of substituted 4-alkyl-2(1H)-quinazolinones. Bandurco VT; Schwender CF; Bell SC; Combs DW; Kanojia RM; Levine SD; Mulvey DM; Appollina MA; Reed MS; Malloy EA J Med Chem; 1987 Aug; 30(8):1421-6. PubMed ID: 3039135 [TBL] [Abstract][Full Text] [Related]
33. Effects of DN-9693, a selective inhibitor of cyclic AMP phosphodiesterase, in isolated and perfused canine large coronary arteries. Nakane T; Chiba S Jpn J Pharmacol; 1988 Dec; 48(4):507-9. PubMed ID: 2468805 [TBL] [Abstract][Full Text] [Related]
34. Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate. Movsesian MA J Am Coll Cardiol; 1999 Aug; 34(2):318-24. PubMed ID: 10440139 [TBL] [Abstract][Full Text] [Related]
35. Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide. Jones GH; Venuti MC; Alvarez R; Bruno JJ; Berks AH; Prince A J Med Chem; 1987 Feb; 30(2):295-303. PubMed ID: 3027338 [TBL] [Abstract][Full Text] [Related]
36. DN.9693, a phosphodiesterase inhibitor, compared with prostaglandin E1 and prostacyclin in four platelet "function" tests. O'Brien JR; Etherington MD; Salmon GP Thromb Res; 1988 Apr; 50(1):237-41. PubMed ID: 2840751 [No Abstract] [Full Text] [Related]
37. Cardiotonic agents. 2. (Imidazolyl)aroylimidazolones, highly potent and selective positive inotropic agents. Hagedorn AA; Erhardt PW; Lumma WC; Wohl RA; Cantor E; Chou YL; Ingebretsen WR; Lampe JW; Pang D; Pease CA J Med Chem; 1987 Aug; 30(8):1342-7. PubMed ID: 3039132 [TBL] [Abstract][Full Text] [Related]
38. The cyclic AMP system and drug development. Smith CG Adv Enzyme Regul; 1974; 12():187-203. PubMed ID: 4156822 [No Abstract] [Full Text] [Related]
39. Some aspects of the cardiovascular pharmacology of UK 14,275 in patients with coronary artery disease. Jennings K; Jackson PG; Monaghan M; Jewitt DE Br J Clin Pharmacol; 1978 Jan; 5(1):13-8. PubMed ID: 619931 [TBL] [Abstract][Full Text] [Related]
40. Inhibitors of cyclic AMP phosphodiesterase. 4. Synthesis and evaluation of potential prodrugs of lixazinone (N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro-2- oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide, RS-82856). Venuti MC; Alvarez R; Bruno JJ; Strosberg AM; Gu L; Chiang HS; Massey IJ; Chu N; Fried JH J Med Chem; 1988 Nov; 31(11):2145-52. PubMed ID: 2846840 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]